'FDA Could Greenlight New Covid Boosters As Early As Friday' - NBC News
Portfolio Pulse from Happy Mohamed
The FDA plans to approve updated versions of the Covid booster as early as Friday, targeting the XBB.1.5 omicron subvariant. The timeline for authorization could extend into next week. The FDA is considering granting the boosters a full approval license instead of an emergency use authorization. Pfizer and Moderna have indicated the list price for the vaccines will be $110 to $130 per dose. Novavax’s vaccine, available through emergency use authorization, will continue to be covered.
September 06, 2023 | 7:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's updated Covid booster is expected to be approved by the FDA. The company has listed the vaccine price at $110 to $130 per dose.
The FDA's approval of Moderna's updated Covid booster will likely increase the company's vaccine sales, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novavax's vaccine, available through emergency use authorization, will continue to be covered.
The continued coverage of Novavax's vaccine under emergency use authorization will likely sustain the company's vaccine sales, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's updated Covid booster is expected to be approved by the FDA. The company has listed the vaccine price at $110 to $130 per dose.
The FDA's approval of Pfizer's updated Covid booster will likely increase the company's vaccine sales, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100